This combination peptide blends cagrilintide and semaglutide to support significant weight reduction. Dosing involves once-weekly subcutaneous injections, starting with a low dose and gradually increasing over 16 or more weeks as tolerated. The protocol aims for a maintenance dose of 2.4 mg of each peptide weekly.
- Combines an amylin analog (cagrilintide) with a GLP-1 receptor agonist (semaglutide).
- Clinical trials show superior weight reduction compared to single agents.
- Administered once weekly via subcutaneous injection.
- Requires gradual dose titration over several months.
- Designed for accurate measurement using a U-100 insulin syringe.
Reconstitution
Vial strength
10 mg
Bacteriostatic water
3 mL
Concentration
3.33 mg/mL
1 unit = 0.01 mL = 16.7 mcg each peptide
- 1Draw 3.0 mL of bacteriostatic water with a sterile syringe.
- 2Inject the water slowly down the inside wall of the peptide vial, avoiding direct contact with the powder to prevent foaming.
- 3Gently swirl or roll the vial until the peptide is completely dissolved; do not shake.
- 4Label the reconstituted vial with the date and store it in the refrigerator at 2–8 °C (35.6–46.4 °F), protected from light. Use within 30 days.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1-4 | 250 mcg each | 15 units (0.15 mL) |
| Weeks 5-8 | 500 mcg each | 30 units (0.30 mL) |
| Weeks 9-12 | 1000 mcg each | 60 units (0.60 mL) |
| Weeks 13-16 | 1700 mcg each | 102 units (1.02 mL) |
| Week 17+ | 2400 mcg each | 144 units (1.44 mL) |
Protocol detail
| Start | Begin with 0.25 mg of each peptide weekly for the first 4 weeks. |
|---|---|
| Escalate | Increase the dose incrementally every 4 weeks (0.5 mg, then 1.0 mg, 1.7 mg, and finally 2.4 mg of each peptide). |
| Target | Aim for a maintenance dose of 2.4 mg of each peptide weekly by Week 17 and beyond. |
| Frequency | Administer once per week via subcutaneous injection, ideally on the same day each week. |
| Timing | Injections can be done at any consistent time of day; remember to rotate injection sites. |
Overview at a glance
| Goal | Support significant weight reduction through dual amylin and GLP-1 receptor agonism. |
|---|---|
| Schedule | Weekly subcutaneous injections for 16+ weeks, followed by maintenance. |
| Dose Range | 0.25–2.4 mg of each peptide weekly with gradual titration. |
| Reconstitution | Add 3.0 mL of bacteriostatic water to a 10 mg vial for a concentration of ~3.33 mg/mL total. |
| Storage | Lyophilized vials frozen; reconstituted vials refrigerated and used within 30 days. |
How it works
Cagrilintide, a long-acting amylin analog, signals satiety to the brain and slows gastric emptying, thereby reducing appetite. Semaglutide activates GLP-1 receptors, which enhances glucose-dependent insulin release and suppresses glucagon, further aiding appetite control. This combination synergistically targets complementary satiety pathways, leading to more pronounced weight reduction than either peptide alone. Clinical evidence suggests the co-administration of these peptides in a regimen like CagriSema effectively leverages these mechanisms to achieve superior body-weight loss, as they influence different yet complementary aspects of metabolic regulation and appetite suppression.
Reported effects
- Significant body weight reduction (clinical trials show ~15-17% reduction).
- Improved glycemic control in type 2 diabetes.
- Addresses satiety through dual mechanisms.
- Potential for long-term weight management.
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Injection-site reactions (mild and transient).
- Higher doses may increase gastrointestinal side effects.
Storage
Lyophilised (unmixed)
Freeze at -20 °C (-4 °F) in dry, dark conditions; minimize moisture exposure.
After reconstitution
Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze-thaw cycles.
Supplies
| Peptide vials | Consider 1 vial for 8 weeks, 2 vials for 12 weeks, or 3 vials for 16 weeks of protocol. |
|---|---|
| Insulin syringes (U-100) | Approximately 1 syringe per week for the duration of the cycle. |
| Bacteriostatic Water | One 10 mL bottle is sufficient for up to 3 vials (9 mL total needed). |
| Alcohol Swabs | Two swabs per week; a 100-count box is recommended for longer cycles. |
Important notes
- Use new, sterile insulin syringes for each injection and dispose of them in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) weekly to minimize local irritation.
- Inject slowly and wait a few seconds before withdrawing the needle.
- Document your weekly dose and injection site rotation for consistency.
- Gradual titration is essential to mitigate potential gastrointestinal side effects.
Frequently asked questions
What is the primary benefit of combining Cagrilintide and Semaglutide?
The main benefit of this combination is enhanced weight reduction, offering superior results compared to using either peptide alone, as they target different yet complementary pathways for appetite suppression and metabolic control.
How long does it take to see results with Cagrilintide + Semaglutide?
Weight reduction is typically observed over several weeks as the dose is gradually increased. Clinical trials often show significant results after 16 weeks, with continued improvements up to 32 weeks, as the body adapts to the higher doses.
Can I adjust the dosing schedule on my own?
The provided dosing schedule is a gradual titration protocol demonstrated in educational research. It's crucial to follow such protocols closely to allow the body to adapt and minimize potential side effects. Any adjustments should be based on individual research needs for experimental protocols.
What should I do if I experience nausea?
Nausea is a common side effect, especially during dose escalation. The protocol suggests gradual titration to minimize this. If nausea is severe, it may indicate that the current dose is too high, and a temporary reduction might be considered in a research setting, though this educational guide advises strict adherence.
Educational reference only. These figures summarise how Cagrilintide + Semaglutide is commonly described in research literature and supplier documentation, including the Cagrilintide + Semaglutide listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Survodutide (10 mg Vial)
Dual GLP-1/glucagon agonist for metabolic health and weight loss.
Mazdutide (10 mg Vial)
Dual GLP-1/glucagon agonist for weight loss and metabolic improvement.
Mazdutide (5 mg Vial)
Dual GLP-1/glucagon agonist for weight management and metabolic health.
Retatrutide (10 mg Vial)
Triple-agonist peptide for significant weight loss and metabolic health.